GWPharmaceuticalsEpidiolexImageKathyYoungAssociatedPressViaTheCannabistDotCo

“A significant event”: CBD-based pharma drug Epidiolex presented to FDA for approval

Analysts have estimated that Epidiolex could be a $1 billion drug for GW Pharmaceuticals.

A CBD-based pharmaceutical drug in development is one more step closer to potential FDA approval.

Earlier this week, London-based GW Pharmaceuticals plc, which operates in the United States as Greenwich Biosciences, wrapped up its New Drug Application for Epidiolex, a formulation of the cannabis compound cannabidiol (CBD) for the treatment of seizures associated with two specific types of epilepsy: Lennox-Gastaut syndrome and Dravet syndrome.

“The submission is a significant event,” said Steve Schultz, a GW spokesman.

Read More at TheCannabist.co 

Categories
InvestmentsMedicalNewsfeed
Tagged
Big PharmacannabidiolCannabis and the Pharmaceutical Industrycannabis could disrupt pharmaceutical salesCannabis sector affecting pharmaceutical industryCBDCBD and epileptic seizuresCBD and federal lawCBD and medicinal usesCBD and pharamaceutical productsCBD can reduce can reduce epileptic seizuresCBD vs. prescription drugsCBD vs. THCclaims that cannabidiol has medical usesEpidiolexepileptic seizuresFDAGreenwich BiosciencesGW Pharmaceuticalsmedical marijuana and pharmaceutical sectormedical marijuana entering pharmaceuticalsOrphan drugsorphan drugs and cannabispharmaceutical industrypharmaceuticalspharmaceuticals vs. cannabisseizurestherapeutic hemp-derived CBD

Subscribe to Our Post Alerts

We keep your data private and do not share your information with anyone.

Good SEO Starts Here

Most Popular

Jetpack plugin with Stats module needs to be enabled.
Jetpack plugin with Stats module needs to be enabled.
Jetpack plugin with Stats module needs to be enabled.
Jetpack plugin with Stats module needs to be enabled.

Blunt Newswire

UPCOMING EVENTS

There are no upcoming events.

More Upcoming Events

Cannabis Jobs

Back to Top